OPERA Trial
Cross-source consensus on OPERA Trial from 1 sources and 4 claims.
1 sources · 4 claims
Comparisons
Other
Other
Other
Highlighted claims
- OPERA is a multicentre, randomised, double-blind, placebo-controlled superiority clinical trial conducted in specialist PBC clinics in England. — Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid
- Participants are assigned equally to UDCA plus OCA or UDCA plus matched placebo. — Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid
- The trial randomises 106 non-cirrhotic adults within 6 months of PBC diagnosis who are at enhanced risk of not achieving biochemical remission on UDCA alone. — Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid
- The trial uses normalisation of serum ALP and total bilirubin at 26 weeks as its main efficacy target. — Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid